These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2376049)

  • 1. Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin.
    Sutherland F; Borkenhagen K; Temple L; Bryant LD; Lafreniere R
    Cancer Immunol Immunother; 1990; 31(5):312-20. PubMed ID: 2376049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2.
    Kim R; Lafreniere R; Borkenhagen K; Bryant LD
    Cancer Immunol Immunother; 1989; 30(5):283-8. PubMed ID: 2624921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
    Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation.
    Lafreniere R; Borkenhagen K; Bryant LD; Ng E; Hayton S
    J Biol Response Mod; 1990 Feb; 9(1):53-60. PubMed ID: 2181072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.
    Vujanovic NL; Herberman RB; Maghazachi AA; Hiserodt JC
    J Exp Med; 1988 Jan; 167(1):15-29. PubMed ID: 3257251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A inhibition of interleukin 2 gene expression, but not natural killer cell proliferation, after interferon induction in vivo.
    Kasaian MT; Biron CA
    J Exp Med; 1990 Mar; 171(3):745-62. PubMed ID: 1689761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mouse natural killer activity by cyclosporin A.
    Yanagihara RH; Adler WH
    Immunology; 1982 Feb; 45(2):325-32. PubMed ID: 6460686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
    Brunda MJ; Tarnowski D; Davatelis V
    Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine trophoblast can be killed by lymphokine-activated killer cells.
    Drake BL; Head JR
    J Immunol; 1989 Jul; 143(1):9-14. PubMed ID: 2499634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
    Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production.
    Amigorena S; Bonnerot C; Fridman WH; Teillaud JL
    Eur J Immunol; 1990 Aug; 20(8):1781-7. PubMed ID: 1698633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.